Kornimate/medical-research-clean huggingface dataset:
single versus repeat betamethasone in twin pregnancies

Conditions: Twin; Complicating Pregnancy

Summary: thus far no robust data exist as to the effect of repeted course of antenatal corticosteroids in twin pregnancies. the investigators hypothesized that repeat course of betamethasone would further reduce neonatal morbidity in twins born before 34 weeks' gestation when compared with single dose.

observational data suggest benefits in multiple gestations exposed to antenatal corticosteroids, although these studies have not consistently reported a statistical benefit or the benefits achieved in singletons. nevertheless, based on the improved outcomes reported in singleton gestations, one course of antenatal corticosteroids is administered to all patients who are between 24 weeks and 34 weeks of gestation and at risk of delivery within 7 days, irrespective of the fetal number. moreover, "a repeat course" of antenatal corticosteroids should also be considered in women who are less than 34 weeks of gestation who have an imminent risk of preterm delivery within the next 7 days, and whose prior course of antenatal corticosteroids was administered more than 14 days previously, again, irrespective of the fetal number. the objective of the current study is to evaluate fetal outcomes in twin pregnancies following repeat betamethasone administration during pregnancy.

Eligibility criteria:
inclusion criteria: * study group - women who received 2 courses of betamethasone between 24 - 34 weeks' gestation. * control comparison group - women who received 1 course of betamethasone between 24 - 34 weeks' gestation. exclusion criteria: * singletone pregnancies * higher order multiple pregnancies (triplets and above) * known major congenital anomaly

Keywords: betamethasone twin pregnancy repeat course single course
abdominal rectus diastasis (ard) reconstruction

Conditions: Rectus Diastasis

Summary: the aim of this study is to investigate whether abdominal wall reconstruction through laparoscopic surgery can be recommended as a safe treatment alternative for patients with symptomatic rectus diastasis, and if this type of treatment leads to improved quality of life, trunk stability and reduced pain.

investigate whether surgical reconstruction with laparoscopic technique can lead to improved quality of life, trunk stability and reduced pain in patients with symptomatic rectus diastasis. the study will also compare two different laparoscopic surgery methods for abdominal wall reconstruction: narrowing of linea alba with continuous suture with or without mesh.

Eligibility criteria:
inclusion criteria: * rectus diastasis ≥3 cm * bmi =\<28 kg/m2 * non smoker * abdominal instability, * abdominal wall and/or lower back pain despite physical therapy / structured physical exercise for at least 6 months exclusion criteria: * bmi \>28 kg/m2 * smoking * ongoing immunosuppressive therapy * current pregnancy ≥16 weeks gestational age for the last 12 months * pregnant or women who wish to become pregnant * previously extensive abdominal wall surgery incl hernia surgery (not including sectio, appendectomy, small umbilical herniae)

Keywords: laparoscopy mesh reinforcement abdominal stability
salmeterol-fluticasone combined inhaled therapy for non-cystic fibrosis bronchiectasis

Conditions: Bronchiectasis

Summary: the objective of this study is to assess the efficacy and safety of salmeterol-fluticasone （ics and laba）combined inhaled therapy for non-cystic fibrosis（non-cf）bronchiectasis patients with chronic airflow obstruction. moreover, subgroup analysis is performed to explore which populations of bronchiectasis patients this treatment is suitable for.

inhaled ics and laba have proved obvious benefit for asthma or chronic obstructive pulmonary disease (copd) patients. however, there is presently no clear evidence on the effect of ics and laba combined inhaled therapy for non-cf bronchiectasis patients. this study is designed as a prospective, randomized,control trial. patients are divided into two groups, one group inhaled with ics and laba (seretide), another group received routine therapy (oxygen uptake, phlegm dissipation, hemostasis postural drainage and naturopathy).the course of treatment is 12 months. all patients underwent reviews at baseline entry to the study and at months 6 and 12 of treatment. the quality of life (qol) scores：st george's dyspnea score (sgrq score）, modified british medical reserach council（mmrc score) and copd assessment test (cat score); lung function test: forced expiratory volume in one second (fev1）,fev1% predicted, the ratio of forced expiratory volume in one second and forced vital capacity (fev1/fvc%); short-acting β2-adrenergic agonist（saba）use and the incidence of adverse event were monitored throughout the study.

Eligibility criteria:
inclusion criteria: * stable bronchiectasis; have the ability to complete the pulmonary function tests; fev1/fvc\<70%; ≥2 exacerbations within the past year exclusion criteria: * a cigarette smoking history more than 10 pack-years;cystic fibrosis or traction bronchiectasis due to various pulmonary fibrosis; an active pulmonary mycobacterial infection; fungal infection; active sarcoidosis; active allergic bronchopulmonary aspergillosis (abpa); asthma as defined by the global initiative for asthma (gina); patients with severe cardiopulmonary dysfunction; with impaired hepatic or kidney function; with hypogammaglobulinemia or other autoimmune diseases; pregnant or breast-feeding women; or patients with a known intolerance for ics or labas.

Keywords: bronchiectasis ics+laba
mnaual therapy in treatment of carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome

Summary: 2 groups of patients randomized for the treatment.

one group treated with neurodynamic techniques and the the other with the desensitization maneuvers.

Eligibility criteria:
inclusion criteria: * pain and paresthesia at median nerve distribution ,positive tinel sign and positive phalen sign. exclusion criteria: * any sensory and/or motor deficit in either ulnar or radial nerve * age greater than 55 years . * male sex.
music-based mindfulness intervention for elevated race-based anxiety in the black community

Conditions: Anxiety

Summary: this study uses a multiple-baseline design and aims to replicate findings that a digital music-based mindfulness intervention can reduce elevated race-based state anxiety in black americans.


Eligibility criteria:
inclusion criteria: * familiarity with meditation * turns to music for emotional support * elevated trait anxiety (\>=12 on the state trait anxiety inventory - trait \[stait\]-5) * majority of anxiety comes from racism or discrimination (\>=60 on a scale of 0 \[not at all\] to 100 \[entirely\] for the following question; "if you are a racial or ethnic minority, how much do you feel that racism and/or discrimination contribute to your elevated anxiety levels?")." exclusion criteria: -
coexistence of cerebral and coronary atherosclerosis in acute ischemic cerebrovascular disease patients registry

Conditions: Coexistence of Cerebral and Coronary Atherosclerosis; Acute Ischemic Cerebrovascular Disease

Summary: coexistence of cerebral and coronary atherosclerosis in acute ischemic cerebrovascular disease patients registry (cocca) is a single-center observational registry of patients hospitalized for acute ischemic cerebrovascular disease (aicvd) with atherosclerotic changes in both cerebral and coronary arteries. this registry aims to establish quantified risk stratification and prognostic models, as well as suggest effective diagnostic and therapeutic strategies.

atherosclerosis has exerted huge global burden as the common pathological process underlying ischemic heart disease and cerebrovascular disease. a substantial portion of acute ischemic cerebrovascular disease (aicvd) patients have both cerebral and coronary atherosclerosis, which is an omen of poor outcomes. but there is large evidence gap in these high-risk patients' prognosis-related factors, limiting the improvement of care quality. coexistence of cerebral and coronary atherosclerosis in acute ischemic cerebrovascular disease patients registry (cocca) is a single-center prospective observational registry of patients hospitalized for aicvd with atherosclerotic changes in both cerebral and coronary arteries. this registry aims to establish quantified risk stratification and prognostic models, as well as suggest effective diagnostic and therapeutic strategies. the clinical, imaging and laboratory information will be collected at the baseline. during an estimated 5-year follow-up, the vessel-related diagnostic or monitoring procedures, treatment, functional status and new vascular events will be recorded by web-based patients' self-reports, investigators' regular telephone visits.

Eligibility criteria:
inclusion criteria: 1. diagnosed as ischemic stroke or transient ischemic attack (tia). 2. less than 30 days after onset of ischemic stroke or tia symptoms. 3. extracranial or intracranial cerebral atherosclerosis confirmed by vascular ultrasound or ct angiograpgy or mr angiograpgy or digital substraction angiography. 4. coronary atherosclerosis confirmed by ct angiograpgy or mr angiograpgy or digital substraction angiography; or with myocardial ischemia symptoms confirmed using electrocardiogram or echocardiography or cardiac mr; or with a history of percutaneous coronary intervention or coronary artery bypass graft. exclusion criteria: 1. with malignant tumors or poor organ functions or hematologic diseases, whose estimated life expectancy is less than 5 years. 2. patients refuse to participate in the research.

Keywords: acute ischemic cerebrovascular disease cerebral atherosclerosis coronary atherosclerosis coexistence
a comparison of extended versus conventional duration of enoxaparin prophylaxis (i.e., preventive treatment) for venous thromboembolism (vte, i.e., blood clots in the veins) and bleeding event risk in a population with acute medical illness

Conditions: Venous Thromboembolism

Summary: venous thromboembolism (vte), including deep vein thrombosis (dvt) and pulmonary embolism (pe), is associated with an increase in risk of mortality and long-term disability and is a major contributor to global disease burden. participants hospitalized with an acute medical illness are at increased risk of vte. this study a non-interventional study which analyzes data already collected in the optum us clinical database. its aim is to compare conventional versus extended duration prophylaxis with enoxaparin on the incidence of vte and bleeding events in participants hospitalized for acute medical illness. the first date of enoxaparin treatment will be the index date.

the study population will be developed from the optum clinical database in the united states, representing routine clinical practice. study population will comprise of participants hospitalized for an acute medical illness receiving enoxaparin during hospitalization. the first date of enoxaparin treatment will be the index date. the study period will be from february 2010 to september 2021. participants will be followed for 90 days.

Eligibility criteria:
inclusion criteria: * hospitalization for the following acute conditions: * infection * respiratory insufficiency * inflammatory condition * cancer * heart failure * ischemic stroke * initiation of enoxaparin prophylaxis during hospitalization (index date) * age ≥40 years exclusion criteria: * symptomatic vte or major bleeding event 90-days prior to index date * major surgery within (+1,-90) days from index date * ongoing anticoagulation therapy (medication supply within \[-2,-32\] days from index date) * atrial fibrillation * chronic kidney disease (ckd) stages iv and v, or dialysis the above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
a phase 1, dose escalation trial of rp-a601 in subjects with pkp2 variant-mediated arrhythmogenic cardiomyopathy (pkp2-acm)

Conditions: PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM)

Summary: this phase 1 dose escalation trial will assess the safety and preliminary efficacy of a single dose intravenous infusion of rp-a601 in high-risk adult patients with pkp2-acm.


Eligibility criteria:
key inclusion criteria: 1. male or female ≥18 years at the time of signing the informed consent 2. capable and willing to provide signed informed consent 3. clinical diagnosis of acm as defined by the 2010 revised task force criteria (tfc) 4. documentation of a pathogenic or likely pathogenic truncating variant in pkp2 5. history of implantable cardioverter-defibrillator (icd) implantation ≥6 months prior to enrollment 6. pvc frequency ≥500 per 24 hours by ambulatory rhythm monitoring 7. left ventricular ejection fraction by echocardiogram or cmr ≥50% key exclusion criteria: 1. anti-aavrh.74 capsid neutralizing antibody titer of \>1:40 2. cardiomyopathy related to a genetic etiology other than pkp2 truncating variant 3. previous participation in a study of gene transfer or gene editing 4. severe right ventricular (rv) dysfunction 5. new york heart association (nyha) class iv heart failure.

Keywords: arrhythmogenic cardiomyopathy arrhythmogenic right ventricular cardiomyopathy arrhythmogenic right ventricular dysplasia sudden cardiac death genetic cardiomyopathy gene therapy pkp2 arvc arvd acm cardiac arrest ventricular arrhythmia
old school hip-hop: improve alzheimer's disease knowledge

Conditions: Dementia

Summary: the purpose of this research study is to evaluate the knowledge of parents and children with respect to dementia symptoms, risk factors, and response before and after an interactive dementia education program that uses music and dance to enhance a health education curriculum at 1-week and 3-months after the intervention.

public awareness of cardinal alzheimer's disease (ad) symptoms remains low. adults often underestimate personal dementia risk; minority populations are more likely to have low dementia literacy and be unaware of it. cultural dementia belief in minority groups are complex and pose barriers to diagnosis, with dementia symptoms being considered a part of normal aging, or that discussion may be taboo even when recognized. a key barrier to timely ad diagnosis in african americans is delayed physician contact, often years-long, following the onset of first symptoms. despite studies demonstrating that dementia concepts first develop in elementary school periods, apart from our work, no dementia awareness programs focus on children. this intervention therefore addresses a major gap regarding optimal approaches for shifting cultural perceptions of dementia in low-income minority populations and reducing barriers to its timely diagnosis. all r01 aims have been completed in this study.

Eligibility criteria:
inclusion criteria: * 4th and 5th-grade children (ages 9-11y) and their parents (age \> 20 years). * selected new york city public schools with similar socio-demographic composition. exclusion criteria: * schools have already received pilot oshh and the u.s. department of health and human services (hhs) programming.

Keywords: dementia, schools, nutrition, health
trichloroacetic acid for endoscopic tracho-esophageal fistula repair

Conditions: Tracheo Esophageal Fistula

Summary: today endoscopic repair of recurrent tracheesophageal fistula (tef) is a safe procedure. using trichlosiacetic acid 50% (tca) for endoscopic aplication of the fistula was reported with a good results ( 4 cases). there were no serious advers effects. the investigators want to use also tca 50% for endoscopic repair in children with recurrent tef.

today endoscopic repair of recurrent tracheesophageal fistula (tef) is a safe procedure. using trichlosiacetic acid 50% (tca) for endoscopic aplication of the fistula was reported with a good results ( 4 cases). there were no serious advers effects. we want to use also tca 50% for endoscopic repair in children with recurrent tef.

Eligibility criteria:
inclusion criteria: * children age 1 month- 20 years old with recurrent tef. * failure of surgical repair.

Keywords: we will treat children age 1 month to 20 years with recurrent tef after surgical failure
efficacy of hyaluronic acid gel and photobiomodulation on wound healing after surgical gingivectomy

Conditions: Gingival Enlargement

Summary: the aim of this study was to evaluate the effect of hyaluronic acid gel after photobiomodulation on the healing of surgical gingivectomy sites


Eligibility criteria:
inclusion criteria: * chronic inflammatory gingival enlargement grade 2 and 3 according to the gingival overgrowth index by miller and damn. * adequate amount of keratinized tissue. * attachment loss= 0 * well educated patients as post-operative instructions need to be followed precisely. exclusion criteria: * patients with history of smoking * pregnant women * patients with bad oral hygiene * patients who have any known systemic disease that interfere with performance of surgical gingivectomy or periodontal wound healing * patients who have any previous adverse reactions to the products (or similar products) used in this study

Keywords: surgical gingivectomy hyaluronic acid photobiomodulation
minimal stimulation or clomiphene citrate in treatment of polycystic ovary syndrome

Conditions: Polycystic Ovary Syndrome

Summary: the purpose of this study is to compare and determine the the efficacy of minimal stimulation and clomiphene citrate(cc) as the first-line treatment in infertile women with polycystic ovary syndrome(pcos).

all patients received 100 mg cc (clomid®; global napi pharmaceuticals, cairo, egypt) for 5 days starting from day 3 of spontaneous or induced menstruation. in group a (minimal stimulation), 2 vials of highly purified ufsh , 150 iu (fostimon; ibsa, lugano, switzerland, 75 iu/vial) were given im on cycle day 9. a total of 3 cycles was offered to each group.

Eligibility criteria:
inclusion criteria: * pcos * no other infertility factors * no previous use of ovarian stimulation drugs exclusion criteria: * congenital adrenal hyperplasia * cushing syndrome * androgen secreting tumors

Keywords: polycystic ovary syndrome clomiphene citrate minimal stimulation infertility treatment
study of apatinib as 3rd/4th line treatment in patients with advanced non-squamous non-small cell lung cancer harboring wild-type epidermal growth factor receptor (egfr)

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: apatinib is a new kind of selective vascular endothelial growth factor receptor 2(vegfr-2) tyrosine kinase inhibitor (tki). the investigators have finished the preclinical,phase i and phase ii clinical studies and found its promising anti-tumor activity and tolerable toxicities. a disease-control rate of 61.1% and a mpfs of 4.7 months were showed in apatinib phase ii study in patients with nsclc. the study aims to compare the efficacy and safety of apatinib to placebo in advanced non-squamous non-small cell lung cancer patients.


Eligibility criteria:
inclusion criteria: 1. subjects \>/= 18 years and \</=70 years of age at the time of informed consent. 2. advanced relapsed or refractory predominantly nsclc with documented wild-type egfr. 3. at least one measurable lesion according to recist 1.1. 4. failure of second line of chemotherapy. 5. eastern cooperative oncology group (ecog) performance status 0-1. 6. patients must have recovered from any aes of prior treatments before randamization. 7. adequate bone marrow,liver and renal function as assessed by the following laboratory tests conducted within 1 week before randomization. hb ≥ 90g/l; anc≥1.5×10e+9/l; plt≥80×10e+9/l; alt and ast \ 45 ml/min. 8. life expectancy of at least three months. 9. written informed consent and the willingness and ability to comply with all aspects of the protocol. exclusion criteria: 1. presence of types of small-cell, squamous-cell, adeno-squamous-cell lung cancer. 2. pregnant or breast-feeding women. 3. suffered from grade ii or above myocardial ischemia or myocardial infarction, uncontrolled arrhythmias (including qt interval male ≥ 450 ms, female≥ 470 ms).severe or uncontrolled systemic disease such as clinically significant hypertension(systolic pressure \>/= 140 mm hg and/or diastolic pressure \>/= 90 mm hg), and grade iii-iv cardiac insufficiency, according to nyha criteria or echocardiography check: lvef\<50%. 4. factors to affect oral administration(inability to swallow tablets,gi tract resection, chronic bacillary diarrhea and intestinal obstruction). 5. coagulation disfunction,hemorrhagic tendency or receiving anticoagulant therapy\>/= ctcae 2 pneumorrhagia or \>/= ctcae 3 hemorrhage in other organs within 4 weeks. 6. bone fracture or wounds that was not cured. 7. arterial thrombus or phlebothrombosis within 12 months and taking anticoagulant agents. 8. mental diseases and psychotropic substances abuse. 9. previous treatment with an trial agent within 4 weeks 10. previous treatment with vegfr,platelet derived growth factor receptor(pdgfr) tkis. 11. proteinuria ≥ (++) or 24 hours total urine protein \> 1.0 g. 12. other coexisting malignant disease (except basal-cell carcinoma and carcinoma in situ of uterine cervix).

Keywords: non-squamous non-small cell lung cancer wild-type egfr 3rd/4th line treatment apatinib
microbial community transplantation on the armpit/foot

Conditions: Heavy, Bad Body Odour From Armpit; Heavy, Bad Body Odour From Foot

Summary: the malodour generation of a person's armpit/foot is caused by the bacteria thriving on that armpit/foot. in order to alter or reduce once bad body odour or foot odour, the living microbial community on the foot/armpit of a non-malodorous person will be transmitted (or up scaled and transmitted) to the foot/armpit of a malodorous person. the odour is evaluated by a trained smelling panel, the bacteria living on the armpit/foot is examined by means of molecular techniques. the microbial transplantation and its follow-up happens under the supervision of a doctor.


Eligibility criteria:
inclusion criteria: * bad armpit or foot odour
long-term outcomes in patients with covid-19

Conditions: COVID-19

Summary: long-term outcomes from coronavirus disease 2019 (covid-19) are currently unknown. this study will collect daily living status of survivors of covid-19.

the ongoing pandemic of coronavirus disease 2019 (covid-19), due to the newly discovered severe acute respiratory syndrome coronavirus 2 (sar-cov-2), has caused a worldwide increase in hospitalization for pneumonia with multi- organ disease. survival from sepsis is associated with increased risk for mortality for at least 2 years. therefore, substantial sequelae including new physical disability, new cognitive impairment and increased vulnerability to further health deterioration are likely to be seen in survivors of covid-19. the investigators conduct this study to investigate daily living status of survivors of covid-19 using telephone interview questionnaire including activity daily living(adl), modified medical research council(mmrc),modified telephone interview for cognitive status (tics-m), zung self-rating depression scale(sds), carcinologic handicap index (chi), and new york heart association (nyha) functional class.

Eligibility criteria:
inclusion criteria: * survivors who had been admitted in leishenshan hospital for covid-19 patients in wuhan, china exclusion criteria: * patients who were \< 18 years

Keywords: covid-19 long-term outcomes